Refine
Year of publication
Document Type
- Article (32)
Has Fulltext
- yes (32)
Is part of the Bibliography
- no (32)
Keywords
- Allogeneic hematopoietic stem cell transplantation (1)
- Artificial Intelligence (1)
- Azacitidine (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Botanical Collections (1)
- Conservation (1)
- DLI (1)
- Decitabine (1)
- Digitization (1)
- Double-blind placebo-controlled trial (1)
- Economic botany (1)
- Ethnobotany (1)
- Exercise challenge (1)
- Exercise challenge at an ambient temperature (1)
- Exercise challenge in a cold chamber (1)
- Exercise-induced asthma (1)
- Exercise-induced bronchoconstriction (1)
- Exhaled nitric oxide (1)
- Forced expiratory volume in 1 s (1)
- Herbaria (1)
- Hypomethylating agents (1)
- Longchain polyunsaturated fatty acids (1)
- Medicinal plants (1)
- Methacholine challenge test (1)
- Relapse (1)
- Relative importance index (1)
- Research Infrastructure (1)
- Semantics (1)
- Taxonomy (1)
- Traditional medicine (1)
- Usefulness (1)
- Venetoclax (1)
- West Africa (1)
- agriculture (1)
- habitat destruction (1)
- herbarium (1)
- naturalization (1)
- plant diversity (1)
The neutron capture cross section of 58Ni was measured at the neutron time of flight facility n_TOF at CERN, from 27 meV to 400 keV neutron energy. Special care has been taken to identify all the possible sources of background, with the so-called neutron background obtained for the first time using high-precision GEANT4 simulations. The energy range up to 122 keV was treated as the resolved resonance region, where 51 resonances were identified and analyzed by a multilevel R-matrix code SAMMY. Above 122 keV the code SESH was used in analyzing the unresolved resonance region of the capture yield. Maxwellian averaged cross sections were calculated in the temperature range of kT = 5 – 100 keV, and their astrophysical implications were investigated.
Treatment of relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a great challenge. Aiming to evaluate the combination of venetoclax and hypomethylating agents (HMAClax) for the treatment of relapse of myeloid malignancies after alloHSCT, we retrospectively collected data from 32 patients treated at 11 German centers. Venetoclax was applied with azacitidine (n = 13) or decitabine (n = 19); 11 patients received DLI in addition. HMAClax was the first salvage therapy in 8 patients. The median number of cycles per patient was 2 (1–19). All but 1 patient had grade 3/4 neutropenia. Hospital admission for grade 3/4 infections was necessary in 23 patients (72%); 5 of these were fatal. In 30 evaluable patients, overall response rate (ORR) was 47% (14/30, 3 CR MRDneg, 5 CR, 2 CRi, 1 MLFS, 3 PR). ORR was 86% in first salvage patients versus 35% in later salvage patients (p = 0.03). In 6 patients with molecular relapse (MR), ORR was 67% versus 42% in patients with hematological relapse (HR) (n = 24, p = n.s.). After a median follow-up of 8.4 months, 25 patients (78%) had died and 7 were alive. Estimated median overall survival was 3.7 months. Median survival of patients with HMAClax for first versus later salvage therapy was 5.7 and 3.4 months (p = n.s.) and for patients with MR (not reached) compared to HR (3.4 months, p = 0.024). This retrospective case series shows that venetoclax is utilized in various different combinations, schedules, and doses. Toxicity is substantial and patients who receive venetoclax/HMA combinations for MR or as first salvage therapy derive the greatest benefit.